Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Scribe Therapeutics’ Collaboration with Sanofi
Fenwick represented Scribe Therapeutics on the deal. Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced its strategic collaboration and...


























